This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Lee's Pharmaceutical Holdings Limited
Drug Names(s): Istaroxime, PST2744
Description: Intravenous PST2744 is the first compound in the class of SERCA (sarcoplasmic reticulum calcium) agonists to be developed for clinical trials. Contraction of the heart depends on the release of calcium from an intracellular structure called the sarcoplasmic reticulum. Levels of calcium in the sarcoplasmic reticulum are down-regulated in heart failure. PST2744 augments the enzyme responsible for mediating the uptake of calcium into the sarcoplasmic reticulum during the resting phase of the heart (diastole), so more calcium is taken up and then available to be released for the contractile phase (systole). The enzyme is sarcoplasmic reticulum calcium ATPase (adenosine triphosphatase).
PST2744 also inhibits sodium and potassium activated adenosine triphosphatase (Na+/K+-ATPase), an enzyme on cell membranes, which leads to an increase in the intracellular concentration of calcium. While it shares this in common with the inotropic (enhancing contraction) agent digitalis, preclinical studies have suggested PST2744's different effects from digitalis on SERCA and calcium leak from the sarcoplasmic reticulum may lead to a better inotropic-toxicity ratio.
Debiopharm and Sigma-Tau
In June 2006, Debiopharm and Sigma-Tau announced the signature of a research and development(R&D) and commercialisation license agreement for istaroxime. Under the terms of the agreement, Debiopharm has the right to develop and commercialise istaroxime worldwide except in Italy and has an option to acquire similar rights on istaroxime follow-on compounds. Debiopharm will pay an upfront license fee and milestones to sigma-tau and will fund the future clinical development costs for the compound. Upon Debiopharm's completion of the phase II clinical development program, sigma-tau may exercise its semi-exclusive rights to market istaroxime in Spain and France and exclusive rights in Portugal. Royalties will accrue to both Debiopharm and sigma-tau according to a specific contractual mechanism.
Lee's and Sigma-Tau
In May 2012, Lee's entered into an agreement with Sigma-Tau to grant exclusive license o CVie Therapeutics (a subsidiary of...See full deal structure in Biomedtracker
Partners: Sigma-Tau S.p.A. Debiopharm S.A.
Debio 0614 News
Additional information available to subscribers only: